NCT06710925: An ongoing trial by Zhuhai Trinomab Pharmaceutical Co., Ltd.
This trial is ongoing. It must report results 2 years, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06710925 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Monoclonal Antibody TNM001 Injection Against Respiratory Syncytial Virus in High-risk Infants |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 30, 2024 |
| Completion date | Nov. 30, 2027 |
| Required reporting date | Nov. 29, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |